Home/Filings/4/0001213900-18-002972
4//SEC Filing

CAVAZZA PAOLO 4

Accession 0001213900-18-002972

CIK 0000707511other

Filed

Mar 13, 8:00 PM ET

Accepted

Mar 14, 4:30 PM ET

Size

41.2 KB

Accession

0001213900-18-002972

Insider Transaction Report

Form 4
Period: 2018-03-13
Transactions
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+11,584,795$2,664,50325,506,521 total
  • Purchase

    Convertible Promissory Note (right to buy)

    2018-03-13$150000.00/sh2,500,000 total
    Exercise: $0.06From: 2013-09-12Common Stock
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+6,348,878$1,460,24231,855,399 total
CAVAZZA PAOLO
10% Owner
Transactions
  • Purchase

    Convertible Promissory Note (right to buy)

    2018-03-13$150000.00/sh2,500,000 total
    Exercise: $0.06From: 2013-09-12Common Stock
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+6,348,878$1,460,24231,855,399 total
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+11,584,795$2,664,50325,506,521 total
Transactions
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+11,584,795$2,664,50325,506,521 total
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+6,348,878$1,460,24231,855,399 total
  • Purchase

    Convertible Promissory Note (right to buy)

    2018-03-13$150000.00/sh2,500,000 total
    Exercise: $0.06From: 2013-09-12Common Stock
Transactions
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+6,348,878$1,460,24231,855,399 total
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+11,584,795$2,664,50325,506,521 total
  • Purchase

    Convertible Promissory Note (right to buy)

    2018-03-13$150000.00/sh2,500,000 total
    Exercise: $0.06From: 2013-09-12Common Stock
Transactions
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+11,584,795$2,664,50325,506,521 total
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+6,348,878$1,460,24231,855,399 total
  • Purchase

    Convertible Promissory Note (right to buy)

    2018-03-13$150000.00/sh2,500,000 total
    Exercise: $0.06From: 2013-09-12Common Stock
Transactions
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+11,584,795$2,664,50325,506,521 total
  • Purchase

    Convertible Promissory Note (right to buy)

    2018-03-13$150000.00/sh2,500,000 total
    Exercise: $0.06From: 2013-09-12Common Stock
  • Purchase

    Common Stock

    2018-03-13$0.23/sh+6,348,878$1,460,24231,855,399 total
Footnotes (6)
  • [F1]Represents shares sold by Sinaf S.A., a Luxembourg corporation ("Sinaf"), and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Sinaf and Essetifin (the "Sinaf Agreement").
  • [F2]Represents shares sold by Taufin International S.A., a Luxembourg corporation ("Taufin"), and purchased by Essetifin, pursuant to a purchase agreement by and between Taufin and Essetifin.
  • [F3]Represents a $150,000 convertible promissory note (the "Note") sold by Sinaf and purchased by Essetifin for an aggregate of $183,780.82, pursuant to the Sinaf Agreement. The reporting person purchased the Note on September 12, 2013, from the issuer in a private placement. The Note and any accrued interest thereon are convertible at the option of the holder at any time prior to repayment of the Note into common stock at a conversion price of $0.06 per share. The Note is payable upon the written demand of the holder thereof at any time after September 10, 2018 (the "Maturity Date"). Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the Maturity Date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date.
  • [F4]Does not include shares issuable at the election of the reporting person upon conversion of accrued interest into shares of common stock.
  • [F5]Paolo Cavazza previously reported indirect ownership of such securities due to his ownership interest in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin.
  • [F6]Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein.

Issuer

REGENERX BIOPHARMACEUTICALS INC

CIK 0000707511

Entity typeother

Related Parties

1
  • filerCIK 0001163608

Filing Metadata

Form type
4
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 4:30 PM ET
Size
41.2 KB